Alvotech To Develop Biosimilar Assets With US$300m Financing Deal

 
• By Grace Montgomery

Alvotech will further develop its biosimilar assets through a US$300 million financing deal that will also enable the firm to “fuel continued growth” and be used for refinancing existing debt.

Syringe
Alvotech is injecting cash into its biosimilars pipeline • Source: Shutterstock

More from Biosimilars

More from Products